Treatment of neurofibromatosis type II with anlotinib: a case report and literature review

Abstract

Patients with neurofibromatosis type II (NF2) usually require surgical treatment, but the probability of tumor recurrence remains high after surgical resection. Moreover, because most of NF2 lesions involve the facial nerve, the risk of facial nerve injury during the surgery is high. Stereotactic radiotherapy can be used to treat some cases of NF2. However, it is not recommended for treatment of multiple or large tumors, and surgical resection may be more difficult after radiotherapy. Few systemic treatments are available. At present, bevacizumab is considered the first-line drug treatment for fast-growing NF2. However, bevacizumab requires long-term administration, and tumor growth will resume after drug withdrawal. Here, we present a case of NF2 that developed exacerbations after multiple treatments with gamma knife and surgery, and achieved good results after later treatment with anlotinib. Accordingly, we propose that anlotinib may be a valuable treatment option for NF2.

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives

“…There are some drugs and natural products that have 4-hydroxyquinoline moiety, such as the furoquinoline alkaloid Skimmianine, with anticancer and anti-inflammatory effects [129,130]; Cabozantinib, used for the treatment of medullary thyroid cancer [131]; Tasquinimod as an immunomodulator for the treatment of blood cancers [132]; AMG-208 as a clinical trial drug for cancer [133]; Anlotinib, with antineoplastic and anti-angiogenic activities [134,135]; and Delafloxacin as a fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections (Figure 4) [136]. Metal-catalyzed 6-endo-dig azide-yne cyclization of azide-tethered alkynes 112 has been developed for the synthesis of multi-substituted 4-alkoxy quinolines 113-117 (Scheme 23) [142][143][144].…”